title: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.
abstract: OBJECTIVE
  To assess the relative effect of different antihypertensive agents on proteinuria and renal function in patients with diabetes.
  
  
  METHODS
  We used MEDLINE and bibliographies in recent articles to identify studies of the effects of antihypertensive agents on renal function in patients with diabetes.
  
  
  METHODS
  We selected 100 controlled and uncontrolled studies that provided data on renal function, proteinuria, or both, before and after treatment with an antihypertensive agent.
  
  
  METHODS
  Data on blood pressure, renal function, proteinuria, patient characteristics (for example, age, sex, and type of diabetes), and study design (for example, random allocation and the use of a placebo) were extracted from selected studies.
  
  
  RESULTS
  Multiple linear regression analysis indicated that angiotensin-converting enzyme (ACE) inhibitors decreased proteinuria independent of changes in blood pressure, treatment duration, and the type of diabetes or stage of nephropathy, as well as study design (P < 0.0001). Reductions in proteinuria from other antihypertensive agents could be entirely explained by changes in blood pressure. Blood pressure reduction in itself was associated with a relative increase in glomerular filtration rate (regression coefficient [+/- SE], 3.70 +/- .92 mL/min for each reduction of 10 mm Hg in mean arterial pressure; P = 0.0002); however, compared with other agents, ACE inhibitors had an additional favorable effect on glomerular filtration rate that was independent of blood pressure changes (3.41 +/- 1.71 mL/min; P = 0.05).
  
  
  CONCLUSIONS
  Angiotensin-converting enzyme inhibitors can decrease proteinuria and preserve glomerular filtration rate in patients with diabetes. These effects occur independent of changes in systemic blood pressure.
authors.affiliation: Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415.
authors.forename: B L
authors.initials: BL
authors.lastname: Kasiske
authors.forename: R S
authors.initials: RS
authors.lastname: Kalil
authors.forename: J Z
authors.initials: JZ
authors.lastname: Ma
authors.forename: M
authors.initials: M
authors.lastname: Liao
authors.forename: W F
authors.initials: WF
authors.lastname: Keane
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology*; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents